PYXS
Pyxis Oncology·NASDAQ
--
--(--)
--
--(--)
5.82 / 10
Netural
Fund flow metrics score 7.52/10, revealing robust fund flow characteristics. Beneficial Medium and Large trends are challenged by problematic overall, block, Small, and Extra-large signals, indicating positive capital movement. The analyst community expresses overwhelmingly bullish analyst consensus with strong conviction. Ratings composition: Strong Buy(50.0%), Buy(50.0%) representing 2 analyst views.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-19
InstitutionRBC Capital
Times predicted2
Historical Win Rate50.0%
Is money flowing into or out of PYXS?
- PYXS holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.82/10 (Netural).
